Bad news for Bayer's factor XIa inhibitor.

"The German company on Monday said its Oceanic trial studying asundexian as a treatment for atrial fibrillation had shown “inferior efficacy” compared with standard treatment."

https://www.ft.com/content/86e6009a-a252-4a52-a4e4-930a50ef2d5a